IMMUNOCORE HOLDINGS PL

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

20 сен 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

13 сен 2021 16:30:00 Источник Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

10 сен 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

08 сен 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

24 авг 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

11 авг 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

04 июн 2021 09:05:00 Источник Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

27 май 2021 16:30:00 Источник Nasdaq GlobeNewswire

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

18 май 2021 16:10:00 Источник Nasdaq GlobeNewswire

Immunocore Reports First Quarter 2021 Financial Results

12 май 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

28 апр 2021 16:30:00 Источник Nasdaq GlobeNewswire

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

12 апр 2021 16:30:00 Источник Nasdaq GlobeNewswire

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

25 мар 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

10 мар 2021 19:00:00 Источник Nasdaq GlobeNewswire

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

19 фев 2021 07:00:00 Источник Nasdaq GlobeNewswire